Bayer AG

Bayer (OTCPK:BAYZF) remains a long-term Buy, with the stock still undervalued despite ongoing litigation and high debt levels. Litigation risks are easing, with a major Supreme Court win and a key settlement decision expected soon, potentially improving free cash flow. Pharmaceuticals face a patent cliff, but strong growth from Nubeqa, Kerendia, and upcoming launches like asundexian and Beyonttra support future earnings.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, from October 9-12, 2026. Key Facts A post-hoc analysis from the Phase III REVEAL study, which evaluated the investigational PET radiotracer I 124 evuzamitide for the sensitivity and specificity of cardiac amyloidosis based o.

BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer's FDA-approved, hormone-free prescription treatment for moderate to severe hot flashes due to menopause.1 Through the partnership, Hart will share her personal experience with moderate to severe hot flashes due to menopause to help women recognize their symptoms and to encourage more proactive treatmen.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the treatment of adults with chronic kidney disease (CKD) without diabetes who are receiving background standard of care. Key Facts The sNDA was supported by results from the Phase III FIND-CKD trial investigating KERENDIA in adults with CKD without diabete.

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Bayer Aktiengesellschaft (BAYRY) or Roche Holding AG (RHHBY). But which of these two companies is the best option for those looking for undervalued stocks?

The German company, which said its new site in Ohio will create around 600 jobs, is the latest European drugmaker to invest in the U.S.

Bayer's pharmaceuticals unit on Friday unveiled plans to invest $2.2 billion in a new manufacturing ​site in New Albany, Ohio, part of a ‌push to boost the business's US revenue.